John Garner

PLGA from PolySciTech used in development of platelet membrane-coated nanoparticles for lung-cancer treatment

Blog Post created by John Garner on Jul 2, 2019

Delivery of drugs to cancer by nanoparticles is complicated by the presence of clearance mechanisms within the human body which screen the particles and their medicines out before they can have therapeutic effect. One strategy to bypass this is to attach cell-indicating membrane components to the particles so that they present as ‘self’ to the immune system. Recently, researchers at Jilin University (China) used PLGA (AP041) from PolySciTech (www.polyscitech.com) to create docetaxel loaded nanoparticles masked with platelet membranes. This research holds promise for improved therapies against lung-cancer. Read more: Changliang Chi, Fuwei Li, Huibo Liu, Shiyun Feng, Yanjun Zhang, Da Zhou, Rongkui Zhang “Docetaxel-loaded biomimetic nanoparticles for targeted lung cancer therapy in vivo” Journal of Nanoparticle Research July 2019, 21:144 https://doi.org/10.1007/s11051-019-4580-8

 

“Abstract: Although the nanodrug-loading system provides new ideas for the effective treatment of cancer, the lack of active cancer targeting, easy to be cleared by the reticuloendothelial system (RES), and may cause potential safety issues are still problems that needs urgent solution. Herein, the authors fabricated platelet membrane (PM)-coated docetaxel (DTX)-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (PM/PLGA/DTX) that possessed unique advantages for satisfactory lung cancer therapy. The resulting core–shell nanoplatform exhibited proper size (hydrodynamic diameter was 98.2 nm) for the enhanced permeability and retention (EPR) effect, slowed down the release of loaded DTX, and effectively suppressed the growth of tumor cells in vitro. More importantly, due to the immune escape and cancer-targeting capacities of PM, the PM/PLGA/DTX showed long circulation and effective lung tumor-targeting ability. After administration in vivo antitumor activity, the PM/PLGA/DTX significantly inhibited the tumor growth of A549 cell-bearing nude mice. In addition, the PM/PLGA/DTX strongly reduced the DTX toxicity compared with that of free DTX. Therefore, the results here demonstrated this biomimetic nanoparticle is a promising nanosized drug delivery system for targeted lung cancer therapy. Keywords: Platelet membrane Controlled drug delivery Targeted lung cancer therapy Docetaxel Biomimetic nanoparticles Drug toxicity PLGA Nanomedicine”

 

Biotech, Pharma, Cancer, Research (BPCR) is a free, 1-day scientific networking conference hosted by Akina, Inc. on Aug 28, 2019. See more and register to attend at http://bpcrconference.com

Outcomes